Testing effectiveness (Phase 2)Active Not RecruitingNCT04506554
What this trial is testing
Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Who this might be right for
Muscle-Invasive Bladder Carcinoma
Fox Chase Cancer Center 81